 Jose Romero
Concepts (178)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebral Small Vessel Diseases | 6 | 2025 | 7 | 4.930 |
Why?
| | Dementia | 6 | 2025 | 141 | 3.230 |
Why?
| | Stroke | 13 | 2026 | 520 | 2.640 |
Why?
| | Magnetic Resonance Imaging | 18 | 2026 | 1583 | 2.380 |
Why?
| | Brain | 10 | 2025 | 1350 | 1.450 |
Why?
| | Cerebral Hemorrhage | 9 | 2023 | 102 | 1.090 |
Why?
| | Leukoencephalopathies | 1 | 2025 | 15 | 0.930 |
Why?
| | Diffusion Tensor Imaging | 1 | 2025 | 104 | 0.880 |
Why?
| | Alzheimer Disease | 2 | 2022 | 338 | 0.710 |
Why?
| | Risk Factors | 17 | 2026 | 4017 | 0.680 |
Why?
| | Cerebral Amyloid Angiopathy | 4 | 2023 | 4 | 0.660 |
Why?
| | Aged | 21 | 2026 | 10429 | 0.640 |
Why?
| | Humans | 43 | 2026 | 53230 | 0.550 |
Why?
| | Male | 26 | 2026 | 27435 | 0.500 |
Why?
| | Female | 27 | 2026 | 28782 | 0.490 |
Why?
| | Incidence | 9 | 2026 | 1085 | 0.480 |
Why?
| | Middle Aged | 17 | 2026 | 13419 | 0.480 |
Why?
| | Hypertension | 2 | 2020 | 554 | 0.470 |
Why?
| | Longitudinal Studies | 7 | 2025 | 774 | 0.470 |
Why?
| | Thrombolytic Therapy | 3 | 2020 | 114 | 0.460 |
Why?
| | Cohort Studies | 8 | 2025 | 1557 | 0.400 |
Why?
| | Risk Assessment | 5 | 2026 | 1368 | 0.400 |
Why?
| | Brain Ischemia | 3 | 2020 | 162 | 0.390 |
Why?
| | Ischemic Attack, Transient | 2 | 2025 | 59 | 0.390 |
Why?
| | Tick-Borne Diseases | 1 | 2012 | 4 | 0.370 |
Why?
| | Parechovirus | 1 | 2011 | 4 | 0.340 |
Why?
| | Viral Vaccines | 1 | 2011 | 16 | 0.340 |
Why?
| | Brain Infarction | 3 | 2026 | 13 | 0.330 |
Why?
| | Picornaviridae Infections | 1 | 2011 | 22 | 0.330 |
Why?
| | Anti-Bacterial Agents | 3 | 2017 | 830 | 0.330 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2010 | 37 | 0.330 |
Why?
| | Respiratory Sounds | 1 | 2010 | 51 | 0.330 |
Why?
| | Antibodies, Viral | 1 | 2011 | 109 | 0.320 |
Why?
| | RNA, Viral | 1 | 2011 | 123 | 0.320 |
Why?
| | Aged, 80 and over | 9 | 2025 | 3494 | 0.320 |
Why?
| | Respiratory Tract Infections | 1 | 2010 | 82 | 0.310 |
Why?
| | Infant, Premature, Diseases | 1 | 2010 | 97 | 0.310 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 177 | 0.260 |
Why?
| | Coronavirus Infections | 2 | 2020 | 188 | 0.250 |
Why?
| | Nerve Growth Factor | 1 | 2026 | 13 | 0.250 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 184 | 0.240 |
Why?
| | Tissue Plasminogen Activator | 3 | 2021 | 108 | 0.230 |
Why?
| | Sensitivity and Specificity | 2 | 2025 | 867 | 0.230 |
Why?
| | Motor Cortex | 2 | 2002 | 15 | 0.230 |
Why?
| | Reproducibility of Results | 2 | 2025 | 1219 | 0.210 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2023 | 4 | 0.210 |
Why?
| | Intra-Articular Fractures | 1 | 2023 | 4 | 0.210 |
Why?
| | Sex Characteristics | 1 | 2024 | 204 | 0.200 |
Why?
| | Basal Ganglia | 1 | 2023 | 25 | 0.190 |
Why?
| | Infarction | 1 | 2022 | 15 | 0.190 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 132 | 0.190 |
Why?
| | Plaque, Atherosclerotic | 1 | 2022 | 45 | 0.190 |
Why?
| | Carotid Stenosis | 1 | 2022 | 65 | 0.180 |
Why?
| | Electromagnetic Fields | 1 | 2002 | 15 | 0.180 |
Why?
| | Mental Health | 1 | 2024 | 248 | 0.180 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2021 | 98 | 0.170 |
Why?
| | Early Medical Intervention | 1 | 2020 | 13 | 0.160 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2020 | 18 | 0.160 |
Why?
| | Neurology | 1 | 2020 | 33 | 0.160 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 38 | 0.160 |
Why?
| | Iron | 1 | 2021 | 130 | 0.160 |
Why?
| | Radiography, Interventional | 1 | 2020 | 58 | 0.160 |
Why?
| | Data Interpretation, Statistical | 1 | 2020 | 169 | 0.160 |
Why?
| | Societies, Medical | 1 | 2020 | 207 | 0.150 |
Why?
| | Venous Thrombosis | 1 | 2020 | 91 | 0.150 |
Why?
| | tau Proteins | 1 | 2019 | 25 | 0.150 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 146 | 0.150 |
Why?
| | Needs Assessment | 1 | 2020 | 145 | 0.150 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 175 | 0.150 |
Why?
| | Angiogenesis Inhibitors | 1 | 2010 | 186 | 0.140 |
Why?
| | Adult | 7 | 2025 | 14534 | 0.140 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 163 | 0.140 |
Why?
| | Pharmacies | 1 | 2019 | 62 | 0.140 |
Why?
| | United States | 6 | 2026 | 5409 | 0.140 |
Why?
| | Retrospective Studies | 7 | 2023 | 6819 | 0.140 |
Why?
| | Papillomavirus Vaccines | 1 | 2019 | 74 | 0.140 |
Why?
| | Community Pharmacy Services | 1 | 2019 | 71 | 0.140 |
Why?
| | Streptococcus pneumoniae | 1 | 2017 | 27 | 0.140 |
Why?
| | Pneumococcal Vaccines | 1 | 2017 | 16 | 0.130 |
Why?
| | Pneumococcal Infections | 1 | 2017 | 15 | 0.130 |
Why?
| | Endovascular Procedures | 1 | 2020 | 193 | 0.130 |
Why?
| | Arthritis, Infectious | 1 | 2017 | 45 | 0.130 |
Why?
| | Stroke, Lacunar | 1 | 2016 | 2 | 0.130 |
Why?
| | Massachusetts | 3 | 2025 | 35 | 0.130 |
Why?
| | Prevalence | 1 | 2020 | 1034 | 0.130 |
Why?
| | Papillomavirus Infections | 1 | 2019 | 177 | 0.130 |
Why?
| | Emotions | 1 | 2017 | 177 | 0.120 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 477 | 0.120 |
Why?
| | Osteomyelitis | 1 | 2017 | 134 | 0.120 |
Why?
| | Ovarian Neoplasms | 1 | 2010 | 459 | 0.120 |
Why?
| | Stenotrophomonas maltophilia | 1 | 2014 | 7 | 0.110 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2014 | 45 | 0.110 |
Why?
| | Leptin | 1 | 2015 | 151 | 0.110 |
Why?
| | Meningitis, Meningococcal | 1 | 2013 | 3 | 0.100 |
Why?
| | Meningococcal Infections | 1 | 2013 | 3 | 0.100 |
Why?
| | Child, Preschool | 4 | 2020 | 4162 | 0.100 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 2002 | 5 | 0.100 |
Why?
| | Bacteremia | 1 | 2013 | 87 | 0.090 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2002 | 27 | 0.090 |
Why?
| | Evoked Potentials, Motor | 2 | 2002 | 9 | 0.090 |
Why?
| | Infant | 4 | 2017 | 3805 | 0.090 |
Why?
| | Neutrophils | 1 | 2013 | 153 | 0.090 |
Why?
| | DNA, Complementary | 1 | 2002 | 128 | 0.090 |
Why?
| | Tularemia | 1 | 2012 | 19 | 0.090 |
Why?
| | Amyloid beta-Peptides | 2 | 2023 | 65 | 0.090 |
Why?
| | Ehrlichiosis | 1 | 2012 | 15 | 0.090 |
Why?
| | Lyme Disease | 1 | 2012 | 32 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 1232 | 0.090 |
Why?
| | Pandemics | 3 | 2020 | 595 | 0.090 |
Why?
| | Upper Extremity Deep Vein Thrombosis | 1 | 2011 | 4 | 0.090 |
Why?
| | Embolism, Paradoxical | 1 | 2011 | 4 | 0.090 |
Why?
| | Mycobacterium tuberculosis | 1 | 2002 | 250 | 0.080 |
Why?
| | Intracranial Embolism | 1 | 2011 | 29 | 0.080 |
Why?
| | Foramen Ovale, Patent | 1 | 2011 | 32 | 0.080 |
Why?
| | Administration, Intravenous | 2 | 2020 | 73 | 0.080 |
Why?
| | Child | 5 | 2023 | 7379 | 0.080 |
Why?
| | Prospective Studies | 3 | 2020 | 2411 | 0.070 |
Why?
| | Adolescent | 4 | 2023 | 6907 | 0.070 |
Why?
| | Anticoagulants | 2 | 2021 | 280 | 0.070 |
Why?
| | Infant, Premature | 1 | 2010 | 331 | 0.070 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 1723 | 0.070 |
Why?
| | Infant, Newborn | 2 | 2014 | 2913 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2010 | 1049 | 0.070 |
Why?
| | Time Factors | 2 | 2025 | 2991 | 0.060 |
Why?
| | Arkansas | 1 | 2012 | 2068 | 0.060 |
Why?
| | Treatment Outcome | 3 | 2020 | 5595 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2020 | 1212 | 0.060 |
Why?
| | Electromyography | 2 | 2002 | 128 | 0.050 |
Why?
| | Young Adult | 3 | 2020 | 4511 | 0.050 |
Why?
| | Methyltransferases | 1 | 2023 | 28 | 0.050 |
Why?
| | Joints | 1 | 2023 | 19 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2022 | 91 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2022 | 77 | 0.050 |
Why?
| | Radiography | 1 | 2023 | 476 | 0.050 |
Why?
| | Blood Pressure | 1 | 2024 | 518 | 0.050 |
Why?
| | Nerve Net | 1 | 2002 | 77 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2023 | 505 | 0.040 |
Why?
| | Atrophy | 1 | 2020 | 48 | 0.040 |
Why?
| | Polysomnography | 1 | 2020 | 76 | 0.040 |
Why?
| | Neuroimaging | 1 | 2021 | 95 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2023 | 533 | 0.040 |
Why?
| | Boston | 1 | 2020 | 13 | 0.040 |
Why?
| | Endocrine System Diseases | 1 | 2010 | 9 | 0.040 |
Why?
| | Fluid Therapy | 1 | 2020 | 79 | 0.040 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2010 | 26 | 0.040 |
Why?
| | Critical Pathways | 1 | 2020 | 36 | 0.040 |
Why?
| | Vascular Diseases | 1 | 2020 | 75 | 0.040 |
Why?
| | Triage | 1 | 2020 | 65 | 0.040 |
Why?
| | Thrombectomy | 1 | 2020 | 74 | 0.040 |
Why?
| | Brain Mapping | 1 | 2020 | 223 | 0.040 |
Why?
| | Skin Diseases | 1 | 2010 | 117 | 0.040 |
Why?
| | Gastrointestinal Diseases | 1 | 2010 | 130 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 238 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 1180 | 0.030 |
Why?
| | Pharmacists | 1 | 2019 | 155 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2017 | 79 | 0.030 |
Why?
| | Vaccination | 1 | 2019 | 310 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 726 | 0.030 |
Why?
| | Microbial Sensitivity Tests | 1 | 2017 | 274 | 0.030 |
Why?
| | Waist-Hip Ratio | 1 | 2015 | 9 | 0.030 |
Why?
| | Radioimmunoassay | 1 | 2015 | 41 | 0.030 |
Why?
| | Clavulanic Acids | 1 | 2014 | 8 | 0.030 |
Why?
| | Ticarcillin | 1 | 2014 | 8 | 0.030 |
Why?
| | Cardiovascular Diseases | 1 | 2010 | 501 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 445 | 0.030 |
Why?
| | Neisseria meningitidis | 1 | 2013 | 4 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2013 | 71 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2014 | 243 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 934 | 0.020 |
Why?
| | DNA Primers | 1 | 2002 | 202 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2002 | 412 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2002 | 177 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2002 | 374 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2002 | 1133 | 0.020 |
Why?
| | Prognosis | 1 | 2013 | 2118 | 0.020 |
Why?
| | Electric Stimulation | 1 | 2002 | 103 | 0.010 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2002 | 72 | 0.010 |
Why?
| | Cerebral Cortex | 1 | 2002 | 194 | 0.010 |
Why?
|
|
Romero's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|